[go: up one dir, main page]

ES2173124T3 - Composicion de dermatano sulfato utilizado como antitrombotico. - Google Patents

Composicion de dermatano sulfato utilizado como antitrombotico.

Info

Publication number
ES2173124T3
ES2173124T3 ES94927827T ES94927827T ES2173124T3 ES 2173124 T3 ES2173124 T3 ES 2173124T3 ES 94927827 T ES94927827 T ES 94927827T ES 94927827 T ES94927827 T ES 94927827T ES 2173124 T3 ES2173124 T3 ES 2173124T3
Authority
ES
Spain
Prior art keywords
anthrombotic
dermatano
sulfato
composition
thrombolisis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927827T
Other languages
English (en)
Inventor
Akikazu Takada
Junichi Onaya
Mikio Arai
Satoshi Miyauchi
Mamoru Kyogashima
Keiichi Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of ES2173124T3 publication Critical patent/ES2173124T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE DESCRIBE UN ANTITROMBOTICO QUE CONTIENE UN SULFATO DERMATANO O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE EL (DS) COMO INGREDIENTE ACTIVO. EL USO DE UN DERIVADO DS DE UN COMPONENTE DISACARIDO O DE PUNTA QUE TIENE UN VALOR DI-OS DE AL MENOS UN 3% O UN PESO MOLECULAR DE AL MENOS 25.000, SIRVE PARA MANTENER UN NIVEL EFECTIVO DE SANGRE PARA AUMENTAR Y DIRIGIR EFICIENTEMENTE LA PREVENCION O DILACION DE TROMBOS. CUANDO SE UTILIZAN JUNTOS CON UN ACTIVADOR DE TEJIDO PLASMINOGENO (T-PA), EL DS PUEDE ACELERAR NOTABLEMENTE LA TROMBOLISIS Y REDUCE LA CANTIDAD DE T-PA UTILIZADOS. ESTE MEDICAMENTO ES UTIL PARA TRATAR Y PREVENIR VARIOS TIPOS DE TROMBOSIS TALES COMO EL INFARTO DE MIOCARDIO Y EL SINDROME DE COAGULACION INTRAVASCULAR DISEMINADO. ADEMAS, PUEDE INHIBIR LA COAGULACION DE SANGRE EN LA CIRCULACION EXTRACORPORAL TAL COMO EN LA DIALISIS RENAL.
ES94927827T 1993-09-30 1994-09-30 Composicion de dermatano sulfato utilizado como antitrombotico. Expired - Lifetime ES2173124T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26975893 1993-09-30

Publications (1)

Publication Number Publication Date
ES2173124T3 true ES2173124T3 (es) 2002-10-16

Family

ID=17476745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927827T Expired - Lifetime ES2173124T3 (es) 1993-09-30 1994-09-30 Composicion de dermatano sulfato utilizado como antitrombotico.

Country Status (17)

Country Link
US (1) US5801162A (es)
EP (2) EP0671414B1 (es)
JP (1) JP3813169B2 (es)
KR (1) KR950704362A (es)
CN (1) CN1115182A (es)
AT (1) ATE211487T1 (es)
CA (1) CA2150552C (es)
DE (1) DE69429576T2 (es)
DK (1) DK0671414T3 (es)
ES (1) ES2173124T3 (es)
FI (1) FI952593L (es)
HU (1) HU219339B (es)
NO (1) NO308856B1 (es)
PL (2) PL177245B1 (es)
RU (1) RU2153506C2 (es)
SG (1) SG67928A1 (es)
WO (1) WO1995009188A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718024B1 (fr) * 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de l'inflammation.
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
CN1196734A (zh) * 1995-09-19 1998-10-21 生化学工业株式会社 消炎药
AU4996400A (en) 1999-05-10 2000-11-21 The Texas A & M University System A peptide inhibitor of fibrinogen blood clotting
JP2001187740A (ja) * 2000-01-05 2001-07-10 Seikagaku Kogyo Co Ltd 創傷治療剤
JP2001151680A (ja) * 1999-11-24 2001-06-05 Seikagaku Kogyo Co Ltd 鎮痒剤
JP4633232B2 (ja) * 2000-06-22 2011-02-16 生化学工業株式会社 成長因子誘導剤
JP2002080371A (ja) * 2000-06-23 2002-03-19 Seikagaku Kogyo Co Ltd プラスミノーゲンアクチベーター活性促進剤
AU2003243396A1 (en) 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
CN100384884C (zh) * 2006-05-29 2008-04-30 南京健友生物化学制药有限公司 肝素钠副产物中分离提纯硫酸皮肤素和低分子硫酸乙酰肝素的方法
JP4524296B2 (ja) * 2007-03-30 2010-08-11 生化学工業株式会社 発毛促進剤
JP4881246B2 (ja) * 2007-07-13 2012-02-22 生化学工業株式会社 発毛効果増強剤
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
WO2013006906A1 (en) * 2011-07-11 2013-01-17 Commonwealth Scientific And Industrial Research Organisation Dermatan sulphate, pharmaceutical compositions and process for producing same
CN109596742B (zh) * 2018-12-25 2022-04-26 深圳市格利科生物科技有限公司 一种检测硫酸乙酰肝素成品中主要成分含量的方法
CN120437731B (zh) * 2025-07-09 2025-11-04 天津泰达洁净材料有限公司 一种熔喷pbt非织造布复合滤材及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535324A1 (fr) * 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS59138202A (ja) * 1983-01-27 1984-08-08 Rikagaku Kenkyusho 新規な硫酸化アミノ糖含有多糖及びその製造法
IT1208509B (it) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
DE3512909A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Verfahren zur bestimmung von plasminogenaktivatoren (pa)
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
IT1189085B (it) * 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
JPH069042B2 (ja) * 1986-09-10 1994-02-02 日本電気株式会社 共用記憶媒体の順次アクセス制御装置
EP0300099A1 (en) * 1987-07-20 1989-01-25 Akzo N.V. New pentasaccharides
JP2667469B2 (ja) * 1988-10-06 1997-10-27 日本放送協会 撮像管用偏向ヨーク
DE69005251T2 (de) * 1989-10-04 1994-05-05 Akzo Nv Sulfatierte Glykosaminoglykuronane mit antithrombotischer Wirkung.
US5118793A (en) * 1989-10-20 1992-06-02 Washington University Modified heparin cofactor II
US5382570A (en) * 1990-04-23 1995-01-17 Akzo, N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
US5116693A (en) * 1990-05-22 1992-05-26 The United States Of America As Represented By The United States Department Of Energy Unique system of FE/PD for magneto-optical recording and magnetic switching devices
FR2663639B1 (fr) * 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
CA2070813C (en) * 1990-11-05 1996-10-29 Hendrik Coenraad Hemker A method to determine the concentration of anticoagulants
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1251183B (it) * 1991-08-28 1995-05-04 Opocrin Spa Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.
IT1251182B (it) * 1991-08-28 1995-05-04 Opocrin Spa Oligosaccaridi di dermatan solfato, processo per la loro produzione e relative composizioni farmaceutiche.

Also Published As

Publication number Publication date
RU2153506C2 (ru) 2000-07-27
CA2150552C (en) 1999-12-21
HUT73245A (en) 1996-07-29
EP1125977A1 (en) 2001-08-22
DK0671414T3 (da) 2002-04-22
EP0671414A1 (en) 1995-09-13
AU7708594A (en) 1995-04-18
WO1995009188A1 (en) 1995-04-06
EP0671414B1 (en) 2002-01-02
RU95112534A (ru) 1997-03-20
KR950704362A (ko) 1995-11-20
NO952137L (no) 1995-07-26
EP0671414A4 (en) 1995-11-15
CN1115182A (zh) 1996-01-17
SG67928A1 (en) 1999-10-19
US5801162A (en) 1998-09-01
PL309218A1 (en) 1995-10-02
FI952593A0 (fi) 1995-05-29
AU699371B2 (en) 1998-12-03
NO308856B1 (no) 2000-11-06
JP3813169B2 (ja) 2006-08-23
DE69429576T2 (de) 2002-08-22
NO952137D0 (no) 1995-05-30
HU219339B (en) 2001-03-28
FI952593A7 (fi) 1995-07-28
PL177245B1 (pl) 1999-10-29
DE69429576D1 (de) 2002-02-07
FI952593L (fi) 1995-07-28
PL177218B1 (pl) 1999-10-29
HU9501542D0 (en) 1995-07-28
ATE211487T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
ES2173124T3 (es) Composicion de dermatano sulfato utilizado como antitrombotico.
ES2148224T3 (es) Formulacion de rapamicina para inyecciones intravenosas.
KR890000101A (ko) 반월조직의 치료 개선방법 및 치료약제
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
Faddis et al. Tissue toxicity of antiseptic solutions: a study of rabbit articular and periarticular tissues
MX9304530A (es) Suministro topico mejorado de farmacos.
DE69226369D1 (de) System mit erhöhender Hautpenetration für verbesserte topische Verabreichung von Arzneimitteln
MX9402339A (es) Formulacion de proteina.
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
FR2710840B1 (fr) Compositions viscoélastiques hautement concentrées en composés fluorés, leur préparation et leurs utilisations dans le domaine médical et en cosmétique.
AR025449A1 (es) Soluciones farmaceuticas de levosimendan
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
ES2143467T3 (es) Agente terapeutico para el tratamiento de las heridas.
ES2067864T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
KR970705402A (ko) 발작과 심근경색에서 대식세포의 침윤과 연관된 질병과 질환의 치료(treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction)
ES2074037T1 (es) Dimero de la lisozima y composiciones que lo contienen.
BR9807444A (pt) Produto antimicrobial
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
ES2057053T3 (es) Compuestos benzoheterociclicos.
DE69943240D1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671414

Country of ref document: ES